{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-376723","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2026-08-31T20:06:01+00:00","discovered_at":"2026-08-31T20:07:03.014444+00:00","generated_at":"2026-08-31T20:07:10.584189+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PMV Pharma reports 46% ORR in ovarian cancer cohort; NDA submission planned Q1 2027","bullets":["ORR of 46% (35/76) in ovarian cancer cohort; median duration of response 10.0 months, median time to response 1.3 months.","FDA feedback supports NDA for accelerated approval; submission planned Q1 2027.","Enrollment for primary analysis in platinum-resistant/refractory ovarian cancer completed.","Safety: mostly Grade 1/2 AEs, 5% discontinuation due to treatment-related AEs.","Company to present update on all PYNNACLE cohorts at medical conference Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-376723","json":"https://secwatch.observer/filing/0001193125-26-376723.json","markdown":"https://secwatch.observer/filing/0001193125-26-376723.md","text":"https://secwatch.observer/filing/0001193125-26-376723.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000119312526376723/0001193125-26-376723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000119312526376723/d441751d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-31T20:07:10.584189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}